The systemic delivery of liposomal short-chain ceramide that targets NTSR1 limits solid tumor growth in syngeneic and athymic murine models of breast adenocarcinoma [66] by inhibiting NTSR1 translocation into membrane microdomains, which ultimately inhibits the mitogen-activated protein kinase pathway [20]. Here, WNK2 is linked to breast adenocarcinoma.